Skip to main content

Jeanne Bertonis, John Kozarch, Gary Mossman, Bruce Haislip, Bradley Popovich, David Cole


Jeanne Bertonis was named the first chief business officer of Angiotech Pharmaceuticals of Vancouver, B.C., responsible for business and corporate development. Bertonis previously worked for Genzyme and Guidant. She holds a master’s in management from Northwestern University, a master’s in zoology from the University of Massachusetts, and a BA in biology from Vassar College.

John Kozarch has been named to the board of directors of Ligand Pharmaceuticals of San Diego. Kozarich is president, CEO, and CSO of ActivX Biosciences of La Jolla, Calif. He is a biotechnology professor at the Scripps Research Institute. Previously, Kozarchi was vice president at Merck Research Laboratories. Kozarich holds a PhD in biological chemistry from MIT, a BS in chemistry from Boston College, and was an NIH postdoctoral fellow at Harvard University.

Gary Mossman

has been named president of the pharma business unit of Cambrex of East Rutherford, NJ. Previously, Mossman was president of Dixie Chemical. He holds BS degrees in chemical engineering and engineering operations, and a master’s in engineering from Iowa State University.

Bruce Haislip has been named chief financial officer of Tartech, a Bridgewater, NJ, life science marketing consultancy. He holds a master’s degree in finance from Fairleigh Dickinson University.

Tm Bioscience of Toronto has named Bradley Popovich as chairman of its scientific advisory board and a member of its board of directors. Additionally, David Cole has been named to the SAB. Popovich is vice president of operations, Xenon Genetics, of Burnaby, British Columbia, Canada. He holds a PhD in molecular genetics from McGill University. Cole is deputy chief of the department of clinical pathology at the Sunnybrook and Women’s College Health Sciences Center, and a senior scientist at the Health Network Research Institute of the University of Toronto.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.